Erythroleukemia: an Update

Olga K. Weinberg; Daniel A. Arber

doi:10.1007/s11912-021-01060-8

Erythroleukemia: an Update

Olga K. Weinberg, Daniel A. Arber

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Purpose of the Review: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset. Recent Findings: The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL. Summary: In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.

Original language	English (US)
Article number	69
Journal	Current oncology reports
Volume	23
Issue number	6
DOIs	https://doi.org/10.1007/s11912-021-01060-8
State	Published - Jun 2021

Keywords

Acute erythroid leukemia
Clinical presentation
Genomics
Molecular mutations

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s11912-021-01060-8

Cite this

@article{ead67ec08d9547ec8df65b2ecd224602,

title = "Erythroleukemia: an Update",

abstract = "Purpose of the Review: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset. Recent Findings: The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL. Summary: In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.",

keywords = "Acute erythroid leukemia, Clinical presentation, Genomics, Molecular mutations",

author = "Weinberg, {Olga K.} and Arber, {Daniel A.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = jun,

doi = "10.1007/s11912-021-01060-8",

language = "English (US)",

volume = "23",

journal = "Current oncology reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "6",

}

TY - JOUR

T1 - Erythroleukemia

T2 - an Update

AU - Weinberg, Olga K.

AU - Arber, Daniel A.

PY - 2021/6

Y1 - 2021/6

N2 - Purpose of the Review: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset. Recent Findings: The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL. Summary: In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.

AB - Purpose of the Review: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset. Recent Findings: The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL. Summary: In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.

KW - Acute erythroid leukemia

KW - Clinical presentation

KW - Genomics

KW - Molecular mutations

UR - http://www.scopus.com/inward/record.url?scp=85104560640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104560640&partnerID=8YFLogxK

U2 - 10.1007/s11912-021-01060-8

DO - 10.1007/s11912-021-01060-8

M3 - Review article

C2 - 33876292

AN - SCOPUS:85104560640

SN - 1523-3790

VL - 23

JO - Current oncology reports

JF - Current oncology reports

IS - 6

M1 - 69

ER -

Erythroleukemia: an Update

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this